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Debate: We don’t need better dose calculation, it’s doing 
more bad than good  
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Advanced dose calculation algorithms have demonstrated 
excellent performance against measurements for complex 
treatments and heterogeneous phantoms. Thus, it is natural 
to consider those as the best candidates for treatment 
planning. Because the dose calculation is more accurate, so 
will be the treatment and its outcome improved. This seems 
intuitively obvious. 
However, a broader view on our clinical practice may temper 
this conclusion. In our clinical practice, we are using dose 
prescriptions from past experience that was typically based 
on less accurate dose calculation algorithms. Also, we are 
using safety margins for geometrical uncertainties that are 
based on hypothesis that simplify considerably the physics of 
dose deposition, but yet seem to provide adequate coverage 
and safety for the majority of the patients. 
We will show during this debate that changing the dose 
calculation algorithm considering our present practice will 
not necessary have a positive impact for the patients. 
Therefore, the introduction of such algorithms in clinics 
should be made cautiously. 
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Debate: Are we precisely inaccurate in our adaption?  
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This debate will critically discuss recent developments in 
adaptive radiotherapy (ART). Adaptive radiotherapy is being 
introduced in many departments nowadays and one of the 
main question is if there is sufficient evidence to safely do 
so?  
In the debate, the inaccuracies of the process will be 
discussed profoundly. What is the accuracy of the process as 
a whole? Do delineation errors and dose calculation errors 
still make ART really worth the effort? Or can these errors 
safely be corrected for?  
Another aspect that will be discussed is risk management. 
Procedures are often not supported by software released for 
this purpose. In case of e.g. plan selection, different manual 
steps are made which are probably prone to human errors. 
What is the impact of these human errors? On the other 
hand, do we really have to wait for optimal software to be 
release and keep patients treated in a sub-optimal manner?  
Last but not least is the lack of sufficient knowledge on 
tumor spread e.g. in the case of gynecological tumors. If we 
reduce the treatment area, aren't we going to miss our 
target? Will this in the end increase local relapse rates 
instead of reducing toxicity? From a different point of view it 
can be argumented that we will never get knowledge of the 
exact tumor location if we keep treating patients with a (too) 
large safety margin. 
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Debate: Moving away from 2 Gray: are we ready for a 
paradigm shift?  
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A significant proportion of curative schedules still use 
fraction sizes ≤2.0 Gy, mostly on a once-daily basis five times 
per week. These practices are likely to diminish further over 
the next 10 years, driven independently by advances in 
biology and physics. Although randomised trials in the 1980s 
and ‘90s confirmed squamous carcinomas of the head and 
neck and bronchus to be relatively insensitive to fraction size 
compared to the dose-limiting late-reacting normal tissues, it 
is now well established that adenocarcinomas of the breast 
and prostate share comparable, or perhaps greater, 
sensitivity to fraction size than the dose-limiting late normal 
tissues. Hypofractionation is increasingly adopted as a 
standard of care for women with breast cancer, and practices 
are changing for men with prostate cancer too, diseases 
account for 28% and 17%, respectively, of all UK radiotherapy 
courses. High dose brachytherapy and novel external beam 
techniques exclude adjacent normal tissues from the high 
dose zone so effectively that prescribed dose is limited 
mainly, if not exclusively, by tissues in the paths of entry and 
exit beams. The impact of stereotactic radiotherapy in 
common cancers remains to be established, but early results 
for early stage lung cancer look encouraging, particularly 
when the benefits of acceleration are factored in. There is 
therefore ample justification to support a prediction that 
accelerated hypofractionation will be a standard of care for 
the majority of curative treatments well before 2025. 
 
 
